|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM313800219 |
| 003 |
DE-627 |
| 005 |
20231225151340.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108574
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1045.xml
|
| 035 |
|
|
|a (DE-627)NLM313800219
|
| 035 |
|
|
|a (NLM)32805452
|
| 035 |
|
|
|a (PII)S1521-6616(20)30734-8
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Kolios, Antonios G A
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Benralizumab in eosinophilic granulomatosis with polyangiitis complicated by Staphylococcus aureus sepsis
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 16.06.2021
|
| 500 |
|
|
|a Date Revised 16.06.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Eosinophilic Granulomatosis with Polyangiitis (EGPA) is an ANCA-associated small-vessels vasculitis characterized by hypereosinophilia and eosinophilic asthma. EGPA with life-threatening organ involvement, particularly cardiac and central nervous system (CNS), is a medical emergency requiring immediate immunosuppression. We describe a 58-year-old patient with a history of chronic rhinosinusitis and eosinophilic asthma, who presented with fever, hypereosinophilia and systemic inflammation. Diagnostic workup identified a cardiac mass, CNS vasculitis, CNS embolization and Staphylococcus aureus in blood cultures. Due to rapid normalization of blood cultures, the intracardiac mass was not considered as primarily infective. Active EGPA with cardiac and CNS involvement complicated by a secondary S. aureus sepsis was diagnosed. In order to not negatively impact antibacterial immunity in active EGPA, antibiotic therapy was combined with Benralizumab, which was well tolerated and EGPA resolved rapidly. Benralizumab could serve as a therapeutic option for eosinophil-mediated pathologies in severely ill patients where immunosuppressives are initially contraindicated
|
| 650 |
|
4 |
|a Case Reports
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Benralizumab
|
| 650 |
|
4 |
|a Churg-Strauss vasculitis
|
| 650 |
|
4 |
|a EGPA
|
| 650 |
|
4 |
|a Eosinophilic granulomatosis with polyangiitis
|
| 650 |
|
4 |
|a Sepsis
|
| 650 |
|
7 |
|a Anti-Asthmatic Agents
|2 NLM
|
| 650 |
|
7 |
|a Anti-Bacterial Agents
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Monoclonal, Humanized
|2 NLM
|
| 650 |
|
7 |
|a benralizumab
|2 NLM
|
| 650 |
|
7 |
|a 71492GE1FX
|2 NLM
|
| 700 |
1 |
|
|a Lutterotti, Andreas
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kulcsar, Zsolt
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Renner, Tobias
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rudiger, Alain
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nilsson, Jakob
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 222(2021) vom: 30. Jan., Seite 108574
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:222
|g year:2021
|g day:30
|g month:01
|g pages:108574
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108574
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 222
|j 2021
|b 30
|c 01
|h 108574
|